Economy, business, innovation

Markets

Instil Bio Q4 and Full Year 2025 Financial Review

Company Overview Instil Bio is a biotechnology firm focused on advancing innovative therapeutics. The company recently discontinued the clinical development of AXN-2510. Moving forward, Instil Bio will focus its capital on pursuing potential acquisitions and in-licensing opportunities to build a differentiated pipeline. Key Financial Figures For the full year ended December 31, 2025, Instil Bio

Instil Bio Q4 and Full Year 2025 Financial Review Read More »

United Therapeutics Corporation (UTHR) Surges 14.8% to $600.09

UTHR Price $600.09 Change +14.8% Volume 583,710 Insider confidence sends shares soaring. United Therapeutics Corporation surged 14.8% to $600.09 on Monday, March 30, 2026, after a wave of insider buying totaling $12.4 million signaled strong conviction from the company’s top executives and board members. Heavy buying across leadership. The specialty pharmaceutical maker saw significant insider

United Therapeutics Corporation (UTHR) Surges 14.8% to $600.09 Read More »

Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings

TPST|EPS -$6.33|Net Loss $26.3M Tempest Therapeutics, Inc. reported a loss of $6.33 per share for the full year of 2025, as the clinical-stage biotechnology company continued advancing its pipeline of small molecule cancer therapeutics. The company posted a net loss of $26.3M for the year, reflecting the capital-intensive nature of early-stage drug development. The Mill

Tempest Therapeutics, Inc. (TPST) Reports FY2025 Earnings Read More »

Scienture Holdings Inc (MEDS) Reports FY2025 Earnings

MEDS|EPS -$2.70|Rev $431,609|Net Loss $41.5M Scienture Holdings Inc (MEDS) posted FY 2025 basic and diluted EPS of -$2.70. Revenue totaled $431,609 for the year. Revenue of $431,609 was up 216.0% year-over-year. Bottom line showed a net loss of $41.5M. This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may

Scienture Holdings Inc (MEDS) Reports FY2025 Earnings Read More »

PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap

PDSB|EPS -$0.74|Net Loss $34.5M Stock $0.54 (-15.4%) Narrower Loss. PDS Biotechnology Corporation (NASDAQ:PDSB) reported a FY 2025 loss per share of -$0.74, reflecting a 28.2% improvement from the -$1.03 loss posted in the year-ago period. The clinical-stage biotechnology company continues to burn cash as it advances its Versamune platform through development, though the narrowing deficit

PDS Biotechnology Corporation (PDSB) FY 2025 Earnings Recap Read More »

Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings

UNCY|EPS -$1.67|Net Loss $26.6M Unicycive Therapeutics, Inc. (UNCY) posted FY 2025 basic and diluted EPS of -$1.67. Unicycive Therapeutics, Inc. is a Biotechnology company. Bottom line showed a net loss of $26.6M. Wall Street consensus stands at 10 buy, 1 hold, 0 sell. This article was generated with the assistance of AI technology and reviewed

Unicycive Therapeutics, Inc. (UNCY) Reports FY2025 Earnings Read More »

Scroll to Top